Category Archives: "Partners"

AIMS presents the latest on multiple sclerosis treatments
AIMS Presents the Latest on Multiple Sclerosis Treatments Educational Programs for Healthcare Professionals Includes Live Events & [...]
Biogen Idec’s PLEGRIDY approved in the US for the treatment of multiple sclerosis
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Friday, August 15, 2014 [...]
PLEGRIDY (Peginterferon beta-1a) approved in the EU for the treatment of multiple sclerosis
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Wednesday, July 23, 2014 [...]
Teva files citizen petition with the US FDA regarding the complexity of COPAXONE
Teva files Citizen Petition with the U.S. Food and Drug Administration (FDA) regarding the Complexity of COPAXONE® (Glatiramer Acetate) [...]
Genzyme’s Lemtrada approved in Argentina for treatment of multiple sclerosis
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis Monday, June 30, 2014 8:00 am EDT CAMBRIDGE, [...]
Biogen Idec and AbbVie Announce Results from Phase 3 Study Investigating Daclizumab
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple [...]
Genzyme’s Lemtrada resubmission accepted for review by FDA
Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 - Cambridge, Mass. - May 30, 2014 - [...]
Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at congresses
Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses Friday, May 30, 2014 [...]
Biogen Idec announces official partnership with Sailing Sclerosis’ “Oceans of Hope”
Biogen Idec Announces Official Partnership with Sailing Sclerosis Oceans of Hope to Globally Change Perceptions of MS Wednesday, May [...]
EMD Serono data at CMSC & ACTRIMS Annual Meeting reinforces proven efficacy of rebif
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM